Cited by 1,248Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenomics and Rare Diseases

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The IARC TP53 database: New online mutation analysis and recommendations to users

Open access

Olivier, Magali, Eeles, Ros, Hollstein, Monica, Khan, Mohammed A., Harris, Curtis C., Hainaut, Pierre·2002·Human Mutation

DOI 10.1002/humu.10081

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/humu.10081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Greenblatt, 1994, Cancer Res, 54, 4855
Hollstein, 1994, Nucleic Acids Res, 22, 3551
Vahteristo, 2001, Cancer Res, 61, 5718

Sorted by citations

Items 801–900 of 1,000

Genetic and epigenetic landscape of early-onset oral squamous cell carcinoma: Insights of genomic underserved and underrepresented populations
Adorno-Farías, D., Morales, S., Rucatti, G. G., Margarit, S., & Fernández‐Ramires, R. (2024) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2024-0036 · Cited by 11
Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men
Greco, L., Rubbino, F., & Laghi, L. (2022) · Cancers · doi:10.3390/cancers14235797 · Cited by 13
Assessment of Transformed PropertiesIn Vitroand of TumorigenicityIn Vivoin Primary Keratinocytes Cultured for Epidermal Sheet Transplantation
Thepot, A., Desanlis, A., Venet, E., Thivillier, L., Justin, V., Morel, A., de Fraipont, F., Till, M., Krutovskikh, V. A., Tommasino, M., et al. (2010) · Journal of Skin Cancer · doi:10.1155/2011/936546 · Cited by 11
The p53 gene with emphasis on its paralogues in mosquitoes
Chen, T.-H., Wu, Y., Hou, J.-N., Chiu, C., & Chen, W. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.06.006 · Cited by 11
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals
Candido, S., Abrams, S. L., Steelman, L. S., Lertpiriyapong, K., Martelli, A. M., Cocco, L., Ratti, S., Follo, M. Y., Murata, R. M., Rosalen, P. L., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.002 · Cited by 11
Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models
Chan, C. S., Sun, Y., Ke, H., Zhao, Y., Belete, M. K., Zhang, C., Feng, Z., Levine, A. J., & Hu, W. (2020) · Life Science Alliance · doi:10.26508/lsa.202000952 · Cited by 10
Bayesian Gene Set Analysis for Identifying Significant Biological Pathways
Shahbaba, B., Tibshirani, R. J., Shachaf, C. M., & Plevritis, S. K. (2011) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/j.1467-9876.2011.00765.x · Cited by 13
Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations
Tan, Y.-H., Chen, Y. M., Ye, X. Y., Lü, Q., Tretyachenko-Ladokhina, V., Yang, W. Y., Senear, D. F., & Luo, R. (2009) · Biophysical Chemistry · doi:10.1016/j.bpc.2009.08.008 · Cited by 11
Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells
Nowak, R., & Tarasiuk, J. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834f8ab4 · Cited by 11
Recent Developments in Critical Genes in the Molecular Biology of Breast Cancer
Sunpaweravong, S., & Sunpaweravong, P. (2005) · Asian Journal of Surgery · doi:10.1016/s1015-9584(09)60265-7 · Cited by 11
Mutational hotspots in the TP53gene and, possibly, other tumor suppressors evolve by positive selection
Glazko, G. V., Babenko, V. N., Koonin, E. V., & Rogozin, I. B. (2006) · Biology Direct · doi:10.1186/1745-6150-1-4 · Cited by 11
p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie · doi:10.1002/ange.200600611 · Cited by 12
Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates
Scaringe, W. A., Li, K., Gu, D., Hagman, K. D. F., Chen, Z., Hill, K. A., & Sommer, S. S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn190 · Cited by 11
Recent Advances in Understanding Carcinogenicity of Oral Squamous Cell Carcinoma: From Basic Molecular Biology to Latest Genomic and Proteomic Findings.
Mehrotra, R., Vasstrand, E. N., & Ibrahim, S. O. (2004) · PubMed · Cited by 11
Multimodal approach to anaplastic thyroid cancer.
Burnison, C. M., & Lim, S. (2012) · PubMed · Cited by 11
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer
Zeng, B., Huang, P., Du, P., Sun, X., Huang, X., Fang, X., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637431 · Cited by 11
Heterogeneous Biomedical Database Integration using a Hybrid Strategy: A P53 Cancer Research Database
Bichutskiy, V. Y., Colman, R., Brachmann, R. K., & Lathrop, R. H. (2006) · Cancer Informatics · doi:10.1177/117693510600200021 · Cited by 11
Characterization of a new cytogenetic subtype of ductal breast carcinomas
Molist, R., Remvikos, Y., Dutrillaux, B., & Muleris, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207799 · Cited by 11
Detection of p53 Gene Mutations by Nonisotopic RNase Cleavage Assay as a Predictor of Poor Prognosis in Colorectal Cancers
Haseba, M., Hidaka, S., Tsuji, T., Yano, H., Komatsu, H., Sawai, T., Yasutake, T., Nakagoe, T., Tagawa, Y., & Ayabe, H. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1026126522278 · Cited by 11
Application of Biomarkers in Cancer Epidemiology
Montserrat, G.-C., Vermeulen, R. C. H., Sherman, M. E., MOORE, L. E., Smith, M. T., & Rothman, N. (2006) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195149616.003.0006 · Cited by 11
Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
Ebid, O. A. E. H., Arab, L. R. E. E., Saad, A. S., Din, M. E. E., Mostafa, N., & Swellam, M. M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05420-1 · Cited by 11
Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol
Liu, Q., Li, L., Yu, Y., & Wei, G. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04700 · Cited by 11
β-Actin facilitates etoposide-induced p53 nuclear import
Qi, W., Li, J., Pei, X., Ke, Y., Bu, Q., & Ni, X. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0004-2 · Cited by 10
Detecting Causal Variants in Mendelian Disorders Using Whole-Genome Sequencing
Hamzeh, A. R., Andrews, T. D., & Field, M. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1103-6_1 · Cited by 8
Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity
Ulisse, S., Arlot‐Bonnemains, Y., Baldini, E., Morrone, S., Carocci, S., Luigi, L. D., & D’Armiento, M. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0257 · Cited by 10
Regulation of P53 stability in p53 mutated human and mouse hepatoma cells
Hailfinger, S., Jaworski, M., Marx‐Stoelting, P., Wanke, I., & Schwarz, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22519 · Cited by 10
Meta-Analysis Results on the Association Between TP53 Codon 72 Polymorphism With the Susceptibility to Oral Cancer
Lin, Y.-M., Shao, J., Yin, X., Huang, C., Jia, X., Yuan, Y., Wu, C.-J., Zhen, E.-M., Yao, Z.-X., Zeng, X., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01014 · Cited by 10
TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population
Basabaeen, A. A., Abdelgader, E. A., Babekir, E. A., Abdelrahim, S. O., Eltayeb, N. H., Altayeb, O. A., Fadul, E. A., Sabo, A., & Ibrahim, I. K. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.5.1579 · Cited by 10
Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition
Mai, P. L., Sand, S. R., Saha, N., Oberti, M., Dolafi, T., DiGianni, L. M., Root, E. J., Kong, X., Bremer, R. C., Santiago, K. M., et al. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1113 · Cited by 10
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models
Ramelow, J., Brooks, C. D., Gao, L., Almiman, A., Williams, T. M., Villalona-Calero, M. A., & Duan, W. (2020) · BMC Cancer · doi:10.1186/s12885-020-07212-6 · Cited by 10
Functional analysis of chemically-induced mutations at the flounder TP53 locus, the FACIM assay
Cachot, J., Couteau, J., Frébourg, T., Leboulenger, F., & Flaman, J. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.06.003 · Cited by 10
p53 Isoform Δ113p53 in Zebrafish
Chen, J., & Peng, J. (2009) · Zebrafish · doi:10.1089/zeb.2009.0598 · Cited by 10
TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma
Mascelli, S., Nozza, P., Jones, D., Colin, C., Pistorio, A., Milanaccio, C., Ravegnani, M., Consales, A., Witt, O., Morana, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10295 · Cited by 10
Recombinant human adenovirus-p53 therapy for the treatment of nasopharyngeal carcinoma: a meta-analysis
Cheng, Y., Xu, X., & Chen, Z. (2016) · SpringerPlus · doi:10.1186/s40064-016-3574-6 · Cited by 10
Targeted Proteomic Analysis Revealed Kinome Reprogramming during Acquisition of Radioresistance in Breast Cancer Cells
Miao, W., Bade, D., & Wang, Y. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00075 · Cited by 10
Structural Studies on Mechanisms to Activate Mutant p53
Viadiu, H., Fronza, G., & Inga, A. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_7 · Cited by 10
Alternative pathway of transcriptional induction of p21WAF1/Cip1 by cyclosporine A in p53-deficient human glioblastoma cells
Żupańska, A. K., Adach, A., Dziembowska, M., & Kaminska, B. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.01.011 · Cited by 10
Screening of TP53 mutations by DHPLC and sequencing in brain tumours from patients with an occupational exposure to pesticides or organic solvents
Loyant, V., Jaffré, A., Breton, J., Baldi, I., Vital, A., Chapon, F., Dutoit, S., Lécluse, Y., Loiseau, H., Lebailly, P., et al. (2005) · Mutagenesis · doi:10.1093/mutage/gei052 · Cited by 10
Navigating the complexity of p53-DNA binding: implications for cancer therapy
Thayer, K. M., Stetson, S., Caballero, F., Chiu, C., & Han, I. S. M. (2024) · Biophysical Reviews · doi:10.1007/s12551-024-01207-4 · Cited by 9
Role of Apoptosis-Related Proteins P53 and Bcl-2 in the Pathogenesis of Nervous System Diseases
Бажанова, Е. Д., & Kozlov, А. А. (2024) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093024040173 · Cited by 9
The association of p53 codon 72 polymorphism with thyroid cancer in Turkish patients
Aral, C., Çağlayan, S., Özışık, G., Massoumilary, Ş., Sönmez, Ö., Akkіprіk, M., Baloğlu, H., Özata, M., & Özer, A. (2007) · Dspace Repository (Marmara Üniversitesi) · Cited by 9
Evolution of germline TP53 variant classification in children with cancer
Tallis, E., Scollon, S., Ritter, D., & Plon, S. E. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.02.011 · Cited by 9
Measurement of DNA Biomarkers for the Safety of Tissue-Engineered Medical Products, Using Artificial Skin as a Model
Rodriguez, H., O'Connell, C., Barker, P. E., Atha, D. H., Jaruga, P., Birincioğlu, M., Marino, M. A., McAndrew, P., & Dizdaroğlu, M. (2004) · Tissue Engineering · doi:10.1089/1076327042500175 · Cited by 9
Helicobacter pylori infection combined with DENA revealed altered expression of p53 and 14-3-3 isoforms in Gulo mice
Nagappan, A., Park, H. S., Park, K., Hong, G. E., Yumnam, S., Lee, H. J., Kim, M. K., Kim, E. H., Lee, W. S., Lee, W. J., et al. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.09.002 · Cited by 9
Transitions at CpG Dinucleotides, Geographic Clustering of TP53 Mutations and Food Availability Patterns in Colorectal Cancer
Verginelli, F., Bishehsari, F., Napolitano, F., Mahdavinia, M., Cama, A., Malekzadeh, R., Miele, G., Raiconi, G., Tagliaferri, R., & Mariani‐Costantini, R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006824 · Cited by 9
High p53 and MAP1 light chain 3A co-expression predicts poor prognosis in patients with esophageal squamous cell carcinoma
Wang, Z., Peng, X., CHEN, S.-S., NING, F.-L., DU, C.-J., Wang, K., Ma, W., & Cheng, Y. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1451 · Cited by 9
p53 transcriptional pathways in breast cancer: the good, the bad and the complex
Thompson, A. M., & Lane, D. P. (2009) · The Journal of Pathology · doi:10.1002/path.2674 · Cited by 9
Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database
Salnikova, L. E. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8290-1 · Cited by 9
Purification of Recombinant p53 from Sf9 Insect Cells
Sun, X. Z., Nguyen, J., & Momand, J. A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-408-5:17 · Cited by 9
Esophageal Cancer - Cell and Molecular Biology, Biomarkers, Nutrition and Treatment
Jazii, F. R. (2012) · InTech eBooks · doi:10.5772/1196 · Cited by 9
Cancer predisposition syndromes associated with myeloid malignancy
Quinn, E. A., & Nichols, K. E. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.04.003 · Cited by 9
Apparently “BRCA-Related” Breast and Ovarian Cancer Patient With Germline TP53 Mutation
Janavičius, R., Andrėkutė, K., Mickys, U., Rudaitis, V., Brasiūnienė, B., & Griškevičius, L. (2011) · The Breast Journal · doi:10.1111/j.1524-4741.2011.01088.x · Cited by 9
Relative mutation rates of each nucleotide for another estimated from allele frequency spectra at human gene loci
Park, L. (2009) · Genetics Research · doi:10.1017/s0016672309990164 · Cited by 9
Two TP53 germline mutations in a classical Li-Fraumeni syndrome family
van Hest, L. P., Ruijs, M., Wagner, A., van der Meer, C. A., Verhoef, S., Veer, L. J. V., & Meijers-Heijboer, H. E. J. (2007) · Familial Cancer · doi:10.1007/s10689-006-9115-7 · Cited by 9
Tumor Suppressor Genes
Levine, A. J., Hu, W., & Feng, Z. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10003-2 · Cited by 9
P53 mutations in urinary bladder cancer patients from Central Poland
Borkowska, E. M., Binka-Kowalska, A., Constantinou, M. A., Nawrocka, A., Matych, J., & Kałużewski, B. (2007) · Journal of Applied Genetics · doi:10.1007/bf03194676 · Cited by 9
Identification of a novel p53 in‐frame deletion in a Li–Fraumeni‐like family
Schiffman, J. D., Chun, N. M., Fisher, P. G., Dahl, G. V. H., Ford, J. M., & Eggerding, F. A. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21247 · Cited by 9
A model for triplet mutation formation based on error-prone translesional DNA synthesis opposite UV photolesions
Ikehata, H., Ono, T., Tanaka, K., & Todo, T. (2007) · DNA repair · doi:10.1016/j.dnarep.2006.12.011 · Cited by 9
Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection
Shi, H., Calvez‐Kelm, F. L., Olivier, M., & Hainaut, P. L. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_13 · Cited by 9
Somatic mutations in human cancer: applications in molecular epidemiology
Roux, E. L., Gormally, E., & Hainaut, P. L. (2005) · Revue d Épidémiologie et de Santé Publique · doi:10.1016/s0398-7620(05)84603-6 · Cited by 8
p53: It Has It All, But Will It Make It to the Clinic As a Marker in Bladder Cancer?
Real, F. X. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1904 · Cited by 9
TP53 as clinical marker in head and neck cancer
Peltonen, J. K. (2011) · Cited by 9
Are Next-Generation Pathogenicity Predictors Applicable to Cancer?
Ostroverkhova, D., Sheng, Y., & Panchenko, A. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168644 · Cited by 8
Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network
Boutelle, A. M., Mabene, A. R., Yao, D., Xu, H., Wang, M., Tang, Y. J., Lopez, S. S., Sinha, S., Demeter, J., Cheng, R., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01513-8 · Cited by 8
Structural dynamics of the wild-type p53 DNA-binding domain and hotspot mutants reveal oncogenic conformational shifts
Zhao, Z., Wang, G., Wu, X., & Qian, Z. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01257k · Cited by 8
p53 Immunohistochemistry as a biomarker of dysplasia and neoplastic progression in Barrett's oesophagus
Kaye, P. (2015) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2015.04.001 · Cited by 8
Anti-angiogenic activities associated with exposure of environmental smoke solutions from 2-stroke auto-rickshaw
Ejaz, S., Anwar, K., Ashraf, M. A., & Lim, C. W. (2009) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2009.02.002 · Cited by 8
Bioinformatics Study of Cancer-Related Mutations within p53 Phosphorylation Site Motifs
Ji, X., Huang, Q., Yu, L., Nussinov, R., & Ma, B. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813275 · Cited by 8
Oral squamous cell carcinoma of the tongue dorsum with multiple cancer-associated mutations in the TP53 gene
Yamasaki, S., Tani, R., Sakurai, S., Toratani, S., & Okamoto, T. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104774 · Cited by 8
p53 Is Potentially Regulated by Cyclophilin D in the Triple-Proline Loop of the DNA Binding Domain
Kumutima, J., Yao, X., & Hamelberg, D. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00946 · Cited by 8
Evaluation of chemo-preventive efficacy of Ficus religiosa latex extract by flow cytometry analysis and gene expression studies performed by RT-PCR in various cell lines
Saida, L., Tulasi, C. D. S. L. N., & Narasu, M. L. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00182-x · Cited by 8
Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity
Hibino, E., Tenno, T., & Hiroaki, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.869851 · Cited by 8
Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series
Qi, X., Zhang, Z.-F., Gao, X., Qin, S., Bai, Y., Yu, W., He, Q., Yu, F., Zhang, J., Jiang, Y. Y., et al. (2023) · Translational Andrology and Urology · doi:10.21037/tau-22-867 · Cited by 8
Model performance and interpretability of semi-supervised generative adversarial networks to predict oncogenic variants with unlabeled data
Ren, Z., Li, Q., Cao, K., Li, M. M., Zhou, Y., & Wang, K. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05141-2 · Cited by 8
Retaining cytotoxic activity of anthrapyridone CO1 against multidrug resistant cells is related to the ability to induce concomitantly apoptosis and lysosomal death of leukaemia HL60/VINC and HL60/DOX cells
Nowak, R., & Tarasiuk, J. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12042 · Cited by 8
MUT-TP53: a versatile matrix for TP53 mutation verification and publication
Soussi, T., Rubio-Nevado, J. M., & Ishioka, C. (2006) · Human Mutation · doi:10.1002/humu.20395 · Cited by 8
Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards
Al-Kashwan, T. A. J., Houshmand, M., Al-Janabi, A., Melconian, A. K., Al-Abbasi, D., Al-Musawi, M. N., Rostami, M., & Yasseen, A. A. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-466 · Cited by 8
Anti-Tumor Effect of Adenoviral Vector-Mediated p53 Gene Transfer on the Growth of Canine Osteosarcoma Xenografts in Nude Mice
Kanaya, N., Yazawa, M., Goto‐Koshino, Y., Mochizuki, M., Nishimura, R., Ohno, K., Sasaki, N., & Tsujimoto, H. (2011) · Journal of Veterinary Medical Science · doi:10.1292/jvms.10-0570 · Cited by 8
Human Protein 53-Derived Cell-Penetrating Peptides
Suhorutšenko, J., Eriste, E., Copolovici, D. M., & Langel, Ü. (2012) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-012-9302-3 · Cited by 8
Toxicological evaluation of the effects of 2-stroke auto-rickshaw smoke solutions on wound healing
Ejaz, S., Iqbal, A., Rahman, S. A., Bari, F., Ashraf, M. A., Nawaz, M., Lim, C. W., & Kim, B. (2008) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2008.12.003 · Cited by 8
Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 Å resolution
Tu, C., Tan, Y.-H., Shaw, G., Zhou, Z., Bai, Y., Luo, R., & Ji, X. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908003338 · Cited by 8
Mining patterns in disease classification forests
Hu, H. (2010) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2010.06.004 · Cited by 8
Blinded study determination of high sensitivity and specificity microchip electrophoresis‐SSCP/HA to detect mutations in the p53 gene
Hestekin, C. N., Lin, J. S., Senderowicz, L., Jakupciak, J. P., O'Connell, C., RADEMAKER, A. W., & Barron, A. E. (2011) · Electrophoresis · doi:10.1002/elps.201100396 · Cited by 8
p53 Point Mutation is Rare in Meningiomas from Singaporean Patients
Das, A., Tan, W., & Smith, D. R. (2005) · Asian Journal of Surgery · doi:10.1016/s1015-9584(09)60249-9 · Cited by 8
p53 Mutations in Carcinoma of the Esophagus and Gastroesophageal Junction
Sengpiel, C., König, I. R., Rades, D., NOACK, F., Duchrow, M., Schild, S. E., Ludwig, D., & Homann, N. (2009) · Cancer Investigation · doi:10.1080/07357900802161047 · Cited by 8
Variaciones genéticas del gen supresor de tumores TP53: relevancia y estrategias de análisis
Rangel-López, A., Piña‐Sánchez, P., & Salcedo, M. (2006) · Revista de investigaci�n Cl�nica · Cited by 8
Alternative responses of primary tumor cells and glioblastoma cell lines to N,N-bis-(8-hydroxyquinoline-5-yl methyl)-benzyl substituted amines: Cell death versus P53-independent senescence
Beclin (2010) · International Journal of Oncology · doi:10.3892/ijo_00000798 · Cited by 8
The Life Cycle of P53: A Key Target in Drug Development
Finlan, L. E., & Hupp, T. R. (2006) · Springer eBooks · doi:10.1007/0-387-23695-3_7 · Cited by 8
Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties
Omar, S. I., & Tuszyński, J. A. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12480 · Cited by 8
Association of Trp53 arg72pro polymorphic variants with breast cancer - a case control study in south Indian population
Suresh, K., Venkatesan, R., irasekar, R., Bl, K., & Sasikala, K. (2011) · Biology and medicine · Cited by 8
Genetics of adrenocortical disease
Bar-Lev, A., & Annes, J. P. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328352f013 · Cited by 8
A high complex karyotype involving eleven chromosomes including three novel chromosomal aberrations and monoallelic loss of TP53 in case of follicular lymphoma transformed into B-cell lymphoblastic leukemia
Wafa, A., Moassass, F., Liehr, T., Bhatt, S., Aljapawe, A., & Achkar, W. A. (2016) · Molecular Cytogenetics · doi:10.1186/s13039-016-0300-6 · Cited by 8
Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort
Kraemer, D., Azzarello‐Burri, S., Steindl, K., Boonsawat, P., Zweier, M., Dedes, K. J., Joset, P., Fink, D. A., & Rauch, A. M. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20092 · Cited by 9
Wild-type p53 reduces radiation hypermutability in p53-mutated human lymphoblast cells
Zhang, Q., Liu, Y., Zhou, J.-C., Chen, W., Zhang, Y., & Liber, H. L. (2007) · Mutagenesis · doi:10.1093/mutage/gem021 · Cited by 8
Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations
Koulgi, S., Achalere, A., Sonavane, U., & Joshi, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143065 · Cited by 8
Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines
Finn, O. J., Binder, R. J., Brickner, A. G., Butterfield, L. H., Ferris, R. L., Kaliński, P., Okada, H., Storkus, W. J., Whiteside, T. L., & Zarour, H. M. (2009) · doi:10.1002/9783527625970.ch2 · Cited by 8
Oncogenomics Methods and ResourcesPreprint
Furney, S. J., Gundem, G., & López-Bigas, N. (2012) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069229 · Cited by 8
Leveraging protein quaternary structure to identify oncogenic driver mutations
Ryslik, G., Cheng, Y., Modis, Y., & Zhao, H. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0963-3 · Cited by 7
Molecular Oncology of Gall Bladder Cancer
Chaturvedi, A., Kumar, V., & Gupta, S. (2019) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-019-01008-2 · Cited by 7
Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53
Abrams, S. L., Akula, S. M., Martelli, A. M., Cocco, L., Ratti, S., Libra, M., Candido, S., Montalto, G., Cervello, M., Gizak, A., et al. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100780 · Cited by 7

Authors: Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P.
Affiliations: World Health Organization (CH)
German Cancer Research Center (DE)
National Institutes of Health (US)
Corresponding author: Hainaut, Pierre
ORCID: Olivier, Magali
Harris, Curtis C.
Hainaut, Pierre
Venue: Human Mutation
Publisher: Wiley
Published: 2002-05-03
Volume: 19
Issue: 6
Pages: 607-614
ISSN: 1059-7794 (ISSN-L)
1098-1004
DOI: 10.1002/humu.10081
OpenAlex: W2073576377
Cited by: 1,248
References: 14
Citations by year: 2026: 11 · 2025: 20 · 2024: 33 · 2023: 46 · 2022: 33 · 2021: 33 · 2020: 32 · 2019: 31 · 2018: 40 · 2017: 30 · 2016: 37 · 2015: 34 · 2014: 48 · 2013: 43 · 2012: 61
FWCI: 29.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4869 d)
Locations: Human Mutation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: TP53 mutation, somatic mutations, TP53 polymorphisms, mutation patterns, cancer genomics, carcinogen exposure, viral infection, genetic background, database restructuring
MeSH terms: DNA Mutational Analysis, Humans, Mutation, Genes, Tumor Suppressor, Genes, p53, Li-Fraumeni Syndrome, Computational Biology, Internet, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The IARC TP53 database: New online mutation analysis and recommendations to users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks